Srinivas Rao - 14 Mar 2025 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Role
Co-Founder and Chief Executive Officer
Signature
/s/ Ryan Barrett, Attorney-in-fact
Issuer symbol
ATAI
Transactions as of
14 Mar 2025
Net transactions value
$0
Form type
4
Filing time
19 Mar 2025, 19:29:47 UTC
Previous filing
10 Jan 2025
Next filing
24 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATAI Common Shares Options Exercise +175,000 +154% 288,360 14 Mar 2025 Direct F1
holding ATAI Common Shares 3,500 14 Mar 2025 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATAI Common Shares Options Exercise $0 -175,000 -100% $0.000000 0 14 Mar 2025 Common Shares 175,000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units vested on March 14, 2024, the first anniversary of the grant date and 50% vested on March 14, 2025, the second anniversary of the grant date.

Remarks:

Co-Founder and Chief Executive Officer